QBie™ Spotlight: Cellceutix Corp. (OTCQB: CTIX)
What does ProGreen US do?
Leo Ehrlich (CEO – OTCQB: CTIX): “Headquartered in Beverly, Massachusetts, Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix’s psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix has now launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its plans for a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed for the first four patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), a type of Inflammatory Bowel Disease (IBD). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.”
What is the next big goal PGUS is trying to accomplish/what should we keep an eye out for?
Ehrlich: “Cellceutix’s goal is to develop better medicines, advance clinical trials, and enter into strategic partnerships and licensing agreements with the larger pharmaceutical companies. This will result in enhancing shareholder value.”
Why did you join the OTCQB/go public?
Ehrlich: “We felt this was right path at this time for our shareholders, as it would afford us better investor exposure.”
How can members of the microcap community help you?
Ehrlich: “We would like community members to learn about Cellceutix, its growth profile, and the potential of its portfolio. We would encourage members to listen to our recent corporate conference call available on our website http://cellceutix.com/events“
About QBie™ Spotlight:
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.